摘要
目的比较卡维地洛与美托洛尔对维持性血液透析患者心功能的影响。方法选择2022年2月—2023年3月在中国人民解放军联勤保障部队第九〇七医院接受维持性血液透析治疗的患者64例,根据随机数字表法分为卡维地洛组和美托洛尔组,各32例。美托洛尔组给予美托洛尔治疗,卡维地洛组给予卡维地洛治疗,2组均连续治疗6个月。比较2组治疗前后心功能指标[左室舒张末期内径(LVEDD)、室间隔舒张末期厚度(IVSD)、左室射血分数(LVEF)、6 min步行距离(6MWD)]、氧化应激指标[超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽过氧化物酶(GSH-Px)],不良反应。结果治疗6个月后,2组LVEDD、IVSD及MDA水平降低,LVEF及SOD、GSH-Px水平升高,6MWD延长,且卡维地洛组变化幅度大于美托洛尔组(P<0.05或P<0.01)。卡维地洛组与美托洛尔组不良反应总发生率比较差异无统计学意义(9.38%vs.15.63%,χ^(2)=0.143,P=0.705)。结论卡维地洛应用于维持性血液透析治疗中较美托洛尔效果更好,可有效改善患者心功能,减轻氧化应激反应,且安全性高。
Objective To compare the effects of carvedilol and metoprolol on cardiac function in maintenance hemodialysis patients.Methods A total of 64 patients receiving maintenance hemodialysis treatment in the 907th Hospital of the Chinese People′s Liberation Army Joint Logistics Support Force from February 2022 to March 2023 were selected and divided into carvedilol group and metoprolol group according to random number table method,with 32 patients in each group.Metoprolol group was treated with metoprolol,carvedilol group was treated with carvedilol,both groups were treated continuously for 6 months.The cardiac function indexes(LVEDD,IVSD,LVEF,6MWD),oxidative stress indexes(SOD,MDA,GSH-Px)before and after treatment,and adverse reactions of two groups were compared.Results After 6 months of treatment,LVEDD,IVSD and MDA levels in two groups were decreased,LVEF,SOD and GSH-Px levels were increased,6MWD was prolonged,and the change range of carvedilol group was greater than metoprolol group(P<0.05 or P<0.01).There was no significant difference in the total incidence of adverse reactions between carvedilol group and metoprolol group(9.38%vs.15.63%,χ^(2)=0.143,P=0.705).Conclusion Carvedilol is more effective than metoprolol in maintenance hemodialysis treatment,can effectively improve patients′heart function,reduce oxidative stress reaction,and has high safety.
作者
严培
朱俊军
汪翔
YAN Pei;ZHU Junjun;WANG Xiang(Department of Nephrology,907th Hospital of Chinese People′s Liberation Army Joint Logistic Support Force,Fujian Province,Nanping 353000,China)
出处
《临床合理用药》
2025年第2期20-22,26,共4页
Chinese Journal of Clinical Rational Drug Use
